Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in age-related macular degeneration
Refers to article:
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19
Lee M Jampol, Claudia S Moy, Timothy G Murray, Sandra M Reynolds, Daniel M Albert, Andrew P Schachat, Kenneth R Diddie, Robert E Engstrom, Paul T Finger, Kenneth R Hovland, Leonard Joffe, Karl R Olsen, Craig G Wells, COMS Follow-up of Plaqued Eyes Working Group
Ophthalmology
December 2002 (Vol. 109, Issue 12, Pages 2197-2206) Abstract |
Full Text |
Full-Text PDF (162 KB)
With apologies from the authors, a significant error was noted in the article entitled “Subretinal Recombinant Tissue Plasminogen Activator Injection and Pneumatic Displacement of Thick Submacular Hemorrhage in Age-Related Macular Degeneration” (Ophthalmology 2004;111:1201–8). The recombinant tissue plasminogen activator (rt-PA) concentrations throughout the article should have been in μg/ml (micrograms per milliliter), not in mg/ml (milligrams per milliliter). More specifically, the concentration of rt-PA injected into the subretinal space should have read 125 μg/ml instead of mg/ml.
FULL TEXT